Mail

UK markets closed

NIKKEI 225
37,552.16
+113.55(+0.30%)
HANG SENG
16,828.93
+317.24(+1.92%)
CRUDE OIL
83.34
+1.44(+1.76%)
GOLD FUTURES
2,336.40
-10.00(-0.43%)
DOW
38,503.69
+263.71(+0.69%)
Bitcoin GBP
53,226.01
-193.20(-0.36%)

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Theravance Biopharma, Inc. (TBPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

9.22

-0.24

(-2.54%)

At close: 04:00PM EDT

9.22

0.00

(0.00%)

After hours:

04:20PM EDT

Full screen

Trade prices are not sourced from all markets

Previous close	9.46
Open	9.45
Bid	9.17 x 100
Ask	9.23 x 100
Day's range	9.19 - 9.61
52-week range	8.21 - 11.98
Volume	335,572
Avg. volume	368,177

Market cap	447.723M
Beta (5Y monthly)	0.35
PE ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	N/A (N/A)
Ex-dividend date	N/A
1y target est	N/A

All

News

Press releases

PR Newswire
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape
PR Newswire
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023.
PR Newswire
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5 at 10:30 am ET (7:30 am PT/3:30 pm GMT). Members of Theravance Biopharma senior management will be hosting one on one meetings at the conference.

NIKKEI 22537,552.16+113.55(+0.30%)

HANG SENG16,828.93+317.24(+1.92%)

CRUDE OIL83.34+1.44(+1.76%)

GOLD FUTURES2,336.40-10.00(-0.43%)

DOW38,503.69+263.71(+0.69%)

Bitcoin GBP53,226.01-193.20(-0.36%)

What is the true cost of the UK state pension?

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Theravance Biopharma to Participate in an Upcoming Investor Conference

NIKKEI 225
37,552.16
+113.55(+0.30%)

HANG SENG
16,828.93
+317.24(+1.92%)

CRUDE OIL
83.34
+1.44(+1.76%)

GOLD FUTURES
2,336.40
-10.00(-0.43%)

DOW
38,503.69
+263.71(+0.69%)

Bitcoin GBP
53,226.01
-193.20(-0.36%)